WO2003024384A3 - Improved methods for treatment with viral vectors - Google Patents

Improved methods for treatment with viral vectors Download PDF

Info

Publication number
WO2003024384A3
WO2003024384A3 PCT/US2002/030021 US0230021W WO03024384A3 WO 2003024384 A3 WO2003024384 A3 WO 2003024384A3 US 0230021 W US0230021 W US 0230021W WO 03024384 A3 WO03024384 A3 WO 03024384A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
tnfα
therapy
viral vectors
improved methods
Prior art date
Application number
PCT/US2002/030021
Other languages
French (fr)
Other versions
WO2003024384A2 (en
Inventor
Robert E Sobol
Mark Fitchmun
Mangala Hariharan
Xiangming Fang
Original Assignee
Genstar Therapeutics Corp
Robert E Sobol
Mark Fitchmun
Mangala Hariharan
Xiangming Fang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genstar Therapeutics Corp, Robert E Sobol, Mark Fitchmun, Mangala Hariharan, Xiangming Fang filed Critical Genstar Therapeutics Corp
Priority to AU2002341766A priority Critical patent/AU2002341766A1/en
Publication of WO2003024384A2 publication Critical patent/WO2003024384A2/en
Publication of WO2003024384A3 publication Critical patent/WO2003024384A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Abstract

The invention comprises methods for improving treatment with adenoviral vectors by administering one or more tumor necrosis factor alpha (TNFalpha or TNFα) blocker(s) and/or one or more tumor necrosis factor alpha (TNFalpha or TNFα) suppressor(s)/inhibitor(s) and/or thrombopoietin to a patient or subject receiving treatment and/or therapy with one or more adenoviral vectors. The therapy can be therapeutic and/or prophylactic. The TNFα blocker(s) and/or TNFα suppressor(s)/inhibitor(s) and/or thrombopoietin may be administered prior to, concurrent with and/or subsequent to adenoviral vector treatment and/or therapy.
PCT/US2002/030021 2001-09-20 2002-09-20 Improved methods for treatment with viral vectors WO2003024384A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002341766A AU2002341766A1 (en) 2001-09-20 2002-09-20 Improved methods for treatment with viral vectors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32364401P 2001-09-20 2001-09-20
US60/323,644 2001-09-20

Publications (2)

Publication Number Publication Date
WO2003024384A2 WO2003024384A2 (en) 2003-03-27
WO2003024384A3 true WO2003024384A3 (en) 2004-03-11

Family

ID=23260084

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/030021 WO2003024384A2 (en) 2001-09-20 2002-09-20 Improved methods for treatment with viral vectors

Country Status (2)

Country Link
AU (1) AU2002341766A1 (en)
WO (1) WO2003024384A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023044774A1 (en) * 2021-09-24 2023-03-30 Sichuan Clover Biopharmaceuticals, Inc. Tpo mimetic fusion proteins and methods of use submission of sequence listing as ascii text file

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180355B1 (en) * 1998-05-07 2001-01-30 University Of Maryland, Baltimore Method for diagnosing and treating chronic pelvic pain syndrome
US6204052B1 (en) * 1994-08-16 2001-03-20 Introgene B.V. Adenoviral vectors with reduced TNF response and partial E3 region deletion
US6258562B1 (en) * 1996-02-09 2001-07-10 Basf Aktiengesellschaft Human antibodies that bind human TNFα

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204052B1 (en) * 1994-08-16 2001-03-20 Introgene B.V. Adenoviral vectors with reduced TNF response and partial E3 region deletion
US6258562B1 (en) * 1996-02-09 2001-07-10 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6180355B1 (en) * 1998-05-07 2001-01-30 University Of Maryland, Baltimore Method for diagnosing and treating chronic pelvic pain syndrome

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CICHON ET AL.: "Intravenous administration of recombinant adenoviruses causes thrombocytopenia, anemia and erythroblastosis in rabbits", J. GENE MED., vol. 1, 1999, pages 360 - 371, XP002965316 *
DEMETRI G.D.: "Targeted approaches for the treatment of thrombocytopenia", ONCOLOGIST, vol. 6, no. SUPPL. 5, September 2001 (2001-09-01), pages 15 - 23, XP002965317 *
NARUMI ET AL.: "Intermittent, repetitive corticosteroid-induced upregulation of platelet levels after adenovirus-mediated transfer to the liver of a chimeric glucocorticoid-responsive promoter controlling the thrombopoietin cDNA", BLOOD, vol. 92, 1 August 1998 (1998-08-01), pages 822 - 833, XP002104566 *
VALLE ET AL.: "Infliximab", EXPERT OPIN. PHARMACOTHER., vol. 2, June 2001 (2001-06-01), pages 1015 - 1025, XP002965315 *

Also Published As

Publication number Publication date
WO2003024384A2 (en) 2003-03-27
AU2002341766A1 (en) 2003-04-01

Similar Documents

Publication Publication Date Title
WO2002098444A3 (en) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
EP1381280A4 (en) Viral vectors and their use in therapeutic methods
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
CA2400801A1 (en) Treatment of congestive heart failure by pretreated autologous blood
WO2003053349A3 (en) Inhibitors of hepatitis c virus
AU2002350235A1 (en) Combination bacteriolytic therapy for the treatment of tumors
WO2005062972A3 (en) Treatment of cancer with novel anti-il 13 monoclonal antibodies
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
WO2003045494A3 (en) Imiquimod therapies
AU2002254158A1 (en) Medical devices, compositions and methods for treating vulnerable plaque
WO2003013430A3 (en) Benzoquinone ansamycins
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
AU2002303502A1 (en) Improved leads for the treatment of patients with chf
AU2002254482A1 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
EP1712243A4 (en) Gene therapy for tumor using minus-strand rna viral vectors encoding immunostimulatory cytokines
WO2003039458A3 (en) TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α
WO2000045853A3 (en) Treatment of tumors with genetically engineered herpes virus
AU2002333773A1 (en) New hepatitis c virus genotype, and its use as prophylactic, therapeutic and diagnostic agent
WO2000040229A3 (en) Synergistic tumorcidal response induced by histamine
WO2003049804A3 (en) Treatment of genitourinary tract disorders
WO2003024384A3 (en) Improved methods for treatment with viral vectors
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
WO2001072341A3 (en) Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
WO2000078800A3 (en) Combined decorin binding protein and outer surface protein compositions and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP